"""
Question: 1101

Evidence: The work described has not been published previously, it is not under consideration for publication elsewhere, and its publi- cation is approved by all authors.

Rationale: The "Research funding" section explicitly states that the work has not been published previously and is not under consideration elsewhere, confirming that the data presented in this paper is previously unpublished.

Answer: Yes
"""

"""
Question: 1102

Evidence: The analysis of proviral DNA was done on March 2019. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method, and analysis was made studying chromatograms ABI in RECall software. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations.

Rationale: The paper describes the sequencing of HIV proviral DNA for protease, reverse transcriptase, and integrase genes using the Sanger method, which confirms that HIV sequences were generated and analyzed.

Answer: Yes
"""

"""
Question: 1103

Evidence: NA

Rationale: After reviewing the entire paper content, there is no mention of in vitro passage experiments being conducted. The study focuses on clinical samples from HIV-infected patients and does not describe any laboratory-based passage experiments.

Answer: No
"""

"""
Question: 1104

Evidence: NA

Rationale: The paper does not report any in vitro antiretroviral susceptibility data. It focuses on genotypic resistance testing through sequencing of proviral DNA and interpretation using databases, but does not mention phenotypic susceptibility assays or IC50/IC90 values.

Answer: No
"""

"""
Question: 2101

Evidence: NA

Rationale: The paper does not mention GenBank accession numbers for any sequenced HIV isolates. The sequences were analyzed using the Stanford University HIV drug resistance database and Geno2pheno, but no deposition in GenBank is reported.

Answer: No
"""

"""
Question: 2102

Evidence: NA

Rationale: Since no GenBank accession numbers are reported in the paper at all, there are certainly no accession numbers for sequences other than laboratory HIV isolates.

Answer: No
"""

"""
Question: 2103

Evidence: NA

Rationale: The paper does not report any GenBank accession numbers for the sequenced HIV isolates.

Answer: NA
"""

"""
Question: 2202

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. Eleven patients (68.7 %) had DRM. Fig. 1 explains the distribution of these mutations.

Rationale: Table 1 provides detailed mutation information for each individual patient, showing specific mutations found in NRTI, NNRTI, PI, and INSTI categories for each sequenced isolate.

Answer: Yes
"""

"""
Question: 2301

Evidence: We included patients with confirmed HIV infection. The objective of this study is to identify DRM in proviral DNA of HIV- infected patients on ART with LLV.

Rationale: The paper specifically states it studies HIV-infected patients, indicating that HIV-1 is the species being studied, as this is the most common cause of HIV infection worldwide and the paper doesn't mention other HIV species.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: NA

Rationale: The paper does not report the subtypes of the sequenced viruses. It mentions sequencing of PR, RT, and integrase segments but does not provide information about HIV subtypes or clades.

Answer: NA
"""

"""
Question: 2303

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations.

Rationale: The paper explicitly states that three HIV genes were sequenced: protease (PR), reverse transcriptase (RT), and integrase.

Answer: protease, reverse transcriptase, integrase
"""

"""
Question: 2304

Evidence: We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %). Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations.

Rationale: The paper reports successful sequencing of the pol gene segments, specifically reverse transcriptase (RT) and protease (PR), which are both components of the HIV pol gene.

Answer: Yes
"""

"""
Question: 2401

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. This study was authorized by the Ethics Committee of the School of Medicine, Pontificia Universidad Cato ÃÅlica de Chile.

Rationale: The paper states that patients were recruited from Red Salud UC CHRISTUS and the study was authorized by an ethics committee in Chile, indicating the sequences are from Chile.

Answer: Chile
"""

"""
Question: 2402

Evidence: Samples were taken between September 2018 to March 2019. The analysis of proviral DNA was done on March 2019.

Rationale: The paper clearly states that samples were collected between September 2018 and March 2019, and the proviral DNA analysis was performed in March 2019.

Answer: September 2018 to March 2019
"""

"""
Question: 2502

Evidence: Sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The paper explicitly states that sequencing was performed using the Sanger method.

Answer: Yes
"""

"""
Question: 2503

Evidence: NA

Rationale: The paper only mentions Sanger sequencing and does not describe the use of any next-generation sequencing (NGS) technology.

Answer: No
"""

"""
Question: 2504

Evidence: NA

Rationale: The paper does not mention any cloning of samples prior to sequencing. It describes direct sequencing of proviral DNA without cloning steps.

Answer: No
"""

"""
Question: 2505

Evidence: NA

Rationale: The paper does not mention single genome sequencing being performed. It describes standard Sanger sequencing of proviral DNA.

Answer: No
"""

"""
Question: 2506

Evidence: NA

Rationale: The paper does not mention molecular cloning of samples. It describes direct sequencing of proviral DNA using Sanger method without cloning steps.

Answer: No
"""

"""
Question: 2601

Evidence: NA

Rationale: The paper does not report results of plasma HIV sequencing. It specifically focuses on proviral DNA sequencing from PBMCs, not plasma virus sequencing.

Answer: No
"""

"""
Question: 2602

Evidence: The analysis of proviral DNA was done on March 2019. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The paper explicitly describes sequencing of proviral DNA, which is obtained from PBMCs (peripheral blood mononuclear cells), indicating PBMC HIV sequencing was performed.

Answer: Yes
"""

"""
Question: 2603

Evidence: NA

Rationale: The paper does not report any plasma virus sequencing. All sequencing was performed on proviral DNA from PBMCs.

Answer: 0
"""

"""
Question: 2604

Evidence: Ultimately, 16 patients/ samples were included. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: The paper reports that 16 patient samples underwent PBMC virus sequencing for proviral DNA, with successful amplification in 15/16 for RT/PR and 16/16 for integrase.

Answer: 16
"""

"""
Question: 2605

Evidence: Patients must have had two or more consecutive values of HIV VL between 20 and 500 copies RNA/mL. The median HIV VL was 49 copies RNA/mL.

Rationale: All patients had detectable viral load between 20-500 copies/mL, indicating active HIV replication, though at low levels.

Answer: Yes
"""

"""
Question: 2606

Evidence: The analysis of proviral DNA was done on March 2019. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The paper explicitly states that sequencing was performed on proviral DNA, which comes from the proviral DNA reservoir in infected cells.

Answer: Yes
"""

"""
Question: 2701

Evidence: NA

Rationale: The paper does not mention the age of patients or indicate that infants or children were included in the study. The focus is on HIV-infected patients attending medical controls without specifying pediatric population.

Answer: No
"""

"""
Question: 2702

Evidence: NA

Rationale: The paper does not mention that any individuals were participating in a clinical trial. It describes an observational study of patients attending routine medical controls.

Answer: No
"""

"""
Question: 2703

Evidence: NA

Rationale: The paper does not mention clinical trial participation for any individuals, let alone all individuals in the study.

Answer: No
"""

"""
Question: 3101

Evidence: Ultimately, 16 patients/ samples were included.

Rationale: The paper clearly states that 16 patients/samples were included in the study for HIV sequencing.

Answer: 16
"""

"""
Question: 3102

Evidence: Ultimately, 16 patients/ samples were included. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: All 16 included patients underwent HIV sequencing, with successful amplification in 15/16 for RT/PR and 16/16 for integrase.

Answer: Yes
"""

"""
Question: 4101

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: The paper states that all patients were on ART and had been treated for an average of 3.3 years, indicating no ART-naive individuals were included.

Answer: No
"""

"""
Question: 4102

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: The paper explicitly states that all patients were receiving ART and had been treated for an average of 3.3 years, confirming that all individuals were ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: Since all patients were ART-experienced (on treatment for average 3.3 years), there are no ART-naive individuals reported in the paper.

Answer: No
"""

"""
Question: 4104

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: The paper states that all patients were on ART, indicating there were no ART-naive individuals in the study.

Answer: 0
"""

"""
Question: 4105

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. Six of them had exposure to more than one HIV treatment regimen.

Rationale: Table 1 provides detailed ART history including current therapy, previous therapy, and reasons for change for all 16 patients, indicating complete ART history information is provided.

Answer: Yes
"""

"""
Question: 4201

Evidence: NA

Rationale: The paper does not report information on transmitted HIV drug resistance. All patients were ART-experienced, and the study focuses on acquired resistance in patients with low-level viremia on ART.

Answer: No
"""

"""
Question: 4202

Evidence: NA

Rationale: The paper does not report information on pretreatment HIV drug resistance. All patients were already on ART at the time of sampling, and the study focuses on resistance in patients with low-level viremia during treatment.

Answer: No
"""

"""
Question: 4301

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: The paper states that all patients received NRTIs and INSTIs as part of their current ART regimen.

Answer: NRTI, INSTI
"""

"""
Question: 4302

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: The paper explicitly states that all patients received integrase strand transfer inhibitors (INSTIs) as part of their current ART regimen.

Answer: Yes
"""

"""
Question: 4303

Evidence: Only one of the five patients with NNRTI mutations had history of NNRTI exposure. All of PR mutations were accessory mutations and none of those patients had history of exposure to PI.

Rationale: The paper mentions that none of the patients with protease inhibitor mutations had history of PI exposure, indicating that some patients may have received PIs in the past, though not currently.

Answer: Yes
"""

"""
Question: 4304

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: While all patients received the same drug classes (NRTI + INSTI), Table 1 shows variations in the specific drugs within these classes, such as different INSTIs (DTG, RAL, EVG/c) and different NRTI backbones.

Answer: No
"""

"""
Question: 4305

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: The paper states that all patients were currently on INSTI-containing regimens, indicating they are not INSTI-naive.

Answer: No
"""

"""
Question: 4403

Evidence: Six of them had exposure to more than one HIV treatment regimen.

Rationale: The paper explicitly states that six patients had exposure to more than one HIV treatment regimen.

Answer: 6
"""

"""
Question: 4404

Evidence: NA

Rationale: The paper states that six patients had exposure to more than one regimen, but does not specify how many of these received more than two ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: Six of them had exposure to more than one HIV treatment regimen.

Rationale: The paper states that only six patients had exposure to more than one regimen, indicating that not all patients received the same number of ART regimens.

Answer: No
"""

"""
Question: 4406

Evidence: Six of them had exposure to more than one HIV treatment regimen.

Rationale: Since six patients had exposure to more than one regimen, this means not all individuals received only one ART regimen.

Answer: No
"""

"""
Question: 4501

Evidence: Table 1 shows patients receiving DTG-containing regimens including TDF/FTC‚ÄØ+‚ÄØDTG, ABC/3TC/DTG.

Rationale: By examining Table 1, we can count patients receiving DTG: Patients 1, 4, 5, 6, 7, 10, 12, 14, 15, 16 - totaling 10 patients.

Answer: 10
"""

"""
Question: 4502

Evidence: NA

Rationale: The paper does not mention darunavir (DRV) being used by any patients in either current or previous therapies listed in Table 1.

Answer: 0
"""

"""
Question: 5101

Evidence: Eleven patients (68.7 %) had DRM.

Rationale: The paper explicitly states that 11 out of 16 patients (68.7%) had drug resistance mutations.

Answer: 11
"""

"""
Question: 5102

Evidence: Six out of 16 patients (37, 5%) with integrase genotyping, had some mutation that conferred resistance to one or more ARV of that family.

Rationale: The paper states that 6 out of 16 patients (37.5%) had INSTI-resistance mutations.

Answer: 6
"""

"""
Question: 5103

Evidence: NA

Rationale: The paper does not specifically report TDF-resistance mutations. It mentions NRTI mutations but does not specify which drugs they confer resistance to, except for mentioning TAMs (thymidine analog mutations) which typically confer resistance to older NRTIs like AZT rather than TDF.

Answer: NA
"""

"""
Question: 5104

Evidence: Regarding the patients with integrase mutations, all had reduced susceptibility to raltegravir and elvitegravir , and one patient, additionally to dolutegravir (DTG) and bictegravir . The latter was on DTG, had a major mutation for INSTI (E138‚ÄØK). Table 1 shows specific INSTI mutations including E138K, G163R, G163K, E157Q.

Rationale: The paper mentions E138K as a major INSTI mutation, and Table 1 shows additional INSTI mutations including G163R, G163K, and E157Q.

Answer: E138K, G163R, G163K, E157Q
"""

"""
Question: 6101

Evidence: NA

Rationale: The paper does not report any phenotypic susceptibility testing. It only describes genotypic resistance testing through DNA sequencing.

Answer: NA
"""

"""
Question: 6102

Evidence: NA

Rationale: The paper does not report any IC50 or IC90 values, as it does not perform phenotypic susceptibility testing.

Answer: No
"""

"""
Question: 6103

Evidence: NA

Rationale: The paper does not report IC50 fold change values, as it does not perform phenotypic susceptibility testing.

Answer: No
"""

"""
Question: 6104

Evidence: NA

Rationale: The paper does not use any phenotypic susceptibility assay. It relies on genotypic resistance testing through DNA sequencing and database interpretation.

Answer: NA
"""

"""
Question: 6105

Evidence: NA

Rationale: The paper does not report any data about replication capacity of the HIV isolates.

Answer: No
"""

"""
Question: 6106

Evidence: NA

Rationale: The paper does not report phenotypic susceptibility testing for any drugs.

Answer: NA
"""

"""
Question: 7101

Evidence: NA

Rationale: The paper does not describe any site-directed mutations. All sequences were obtained from clinical samples from HIV-infected patients.

Answer: No
"""

"""
Question: 7102

Evidence: NA

Rationale: The paper does not describe any in vitro passage experiments. All sequences were obtained directly from clinical samples without laboratory passage.

Answer: No
"""